{"nctId":"NCT00811954","briefTitle":"Comparative Study of Three NNRTI-Sparing HAART Regimens","startDateStruct":{"date":"2009-05"},"conditions":["HIV Infection"],"count":1814,"armGroups":[{"label":"Arm A: ATV/RTV + FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine/tenofovir disoproxil fumarate","Drug: Ritonavir","Drug: Atazanavir"]},{"label":"Arm B: RAL + FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine/tenofovir disoproxil fumarate","Drug: Raltegravir"]},{"label":"Arm C: DRV/RTV + FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine/tenofovir disoproxil fumarate","Drug: Darunavir","Drug: Ritonavir"]}],"interventions":[{"name":"Emtricitabine/tenofovir disoproxil fumarate","otherNames":["TDF/FTC"]},{"name":"Raltegravir","otherNames":["RAL"]},{"name":"Darunavir","otherNames":["DRV"]},{"name":"Ritonavir","otherNames":["RTV"]},{"name":"Atazanavir","otherNames":["ATV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 infected\n* No evidence of any exclusionary mutations defined as any major NRTI or PI resistance-associated mutation on any genotype or evidence of significant NRTI or PI resistance on any phenotype performed at any time prior to study entry. NNRTI-associated resistance mutations are not excluded. More information on this criterion can be found in the study protocol.\n* No prior anti-HIV therapy. More information on this criterion can be found in the study protocol.\n* Viral load is 1000 copies/mL or higher, as measured within 90 days prior to study entry\n* Certain laboratory values obtained within 60 days prior to study entry\n* Ability to obtain RTV by prescription\n* Completed cardiovascular risk assessment. More information on this criterion can be found in the study protocol.\n* Must agree to use acceptable forms of contraception while receiving study drugs and for 6 weeks after stopping the medications. More information on this criterion is available in the protocol.\n* Negative pregnancy test within 72 hours before initiating antiretroviral medication\n* Participating in research at any AIDS Clinical Trial Group (ACTG) clinical research site or select International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group sites\n* Ability and willingness of subject or legal guardian/representative to give written informed consent\n\nExclusion Criteria:\n\n* Use of immunomodulators, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry. Those using stable physiologic glucocorticoid doses, a short course of pharmacologic glucocorticoid, corticosteroids for acute therapy treating an opportunistic infection, inhaled or topical corticosteroids, or granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) will not be excluded.\n* Known allergy or sensitivity to study drugs or their ingredients. A history of sulfa allergy is not excluded.\n* Any condition that, in the opinion of the investigator, would compromise the participant's ability to participate in the study\n* Serious illness requiring systemic treatment and/or hospitalization until participant either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 7 days prior to study entry\n* Requirement for any current medications that are prohibited with any study drugs\n* Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness\n* Any prior use of entecavir for treatment of hepatitis B for greater than 8 weeks while the participant was known to be HIV infected\n* Presence of decompensated cirrhosis\n* Pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Probability of First Virologic Failure by Week 96","description":"The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 96.\n\nTime to virologic failure was defined as the first time from study entry to the first of two consecutive HIV-1 RNA \\>1000 copies/mL at or after week 16 and before week 24, or \\>200 copies/mL at or after week 24. Week 16 is defined to occur between 14 (98 days) and 18 weeks (126 days) after study entry, week 24 is defined to occur between 22 (154 days) and 26 (182 days) after study entry, and week 96 is defined to occur between 88 (616 days) and 104 (728 days) after study entry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96","description":"The cumulative incidence of discontinuation for toxicity by week 96 was estimated using competing risks with treatment discontinuation for other reasons considered as a competing event; participants completing the study on the RAL or PI component of their randomized regimen were considered censored at the earliest of the date of last patient contact and off study date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of First Adverse Event by Week 96","description":"The cumulative incidence of first adverse event (with and without total bilirubin and creatine kinase and measured from study entry) by week 96 was estimated using methods for competing risks. Discontinuation of randomized treatment prior to an adverse event was considered a competing event.\n\nThe time to the first of any post-entry Grade 2, 3, or 4 sign or symptom, or Grade 3 or 4 laboratory abnormality while on randomization. The protocol required reporting of signs and symptoms and laboratory values as follow: all signs and symptoms grade ≥2 post-entry to week 48, signs and symptoms grade \\>3 after week 48, and laboratory values grade \\>3 and all signs, symptoms, and laboratory values that led to a change in treatment, regardless of grade throughout out all post-entry follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96","description":"The Kaplan-Meier estimate of the cumulative probability of TROVR by week 96.\n\nA composite TLOVR endpoint defined in the CDER of the FDA document \"Guidance for Industry - Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Consideration for Accelerated and Traditional Approval\" (Appendix B, pages 20) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.\n\nIf participants never achieved a confirmed HIV-1 RNA≤200 cp/mL (on two consecutive visits) prior to death, permanent discontinuation of randomized treatment, or time of last available HIV-1 RNA evaluation, TLOVR was equal to 0; otherwise, TLOVR was the earliest time of permanent discontinuation of randomized treatment prior to study close-out period, time to confirmed levels \\>200 cp/mL, or time to death. If TLOVR is immediately preceded by a single missing scheduled visit or multiple consecutive missing scheduled visits, TLOVR is replaced by the first such missing visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Mutations Associated With NRTI Resistance","description":"The number of participants with NRTI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance","description":"The number of participants with ATV/RTV or DRV/RTV resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Mutations Associated With INI Resistance","description":"The number of participants with INI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"CD4+ T-cell Count","description":"The absolute levels of CD4+ T-cell counts (cells/mm3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"462","spread":null},{"groupId":"OG001","value":"460","spread":null},{"groupId":"OG002","value":"457","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"524","spread":null},{"groupId":"OG001","value":"526","spread":null},{"groupId":"OG002","value":"509","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"587","spread":null},{"groupId":"OG001","value":"596","spread":null},{"groupId":"OG002","value":"564","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"622","spread":null},{"groupId":"OG001","value":"631","spread":null},{"groupId":"OG002","value":"596","spread":null}]}]}]},{"type":"SECONDARY","title":"CD4+ T-cell Count Changes From Baseline","description":"Change was calculated as the CD4+ T-cell count at week (24, 48, 96, and 144) minus the baseline CD4+ T-cell count","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"218","spread":null},{"groupId":"OG002","value":"201","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"288","spread":null},{"groupId":"OG002","value":"256","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"325","spread":null},{"groupId":"OG002","value":"288","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Death or AIDS Defining Events (CDC Category C)","description":"The incidence of death or AIDS defining events (CDC category C) was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":null},{"groupId":"OG001","value":"1.64","spread":null},{"groupId":"OG002","value":"2.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD)","description":"The incidence of targeted serious non-AIDS defining events was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":null},{"groupId":"OG001","value":"2.24","spread":null},{"groupId":"OG002","value":"2.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Total Cholesterol Level From Baseline","description":"Only fasting results are included. Change was calculated as the fasting total cholesterol at week (48, 96, and 144) minus the baseline fasting total cholesterol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting HDL Cholesterol Level From Baseline","description":"Only fasting results are included. Change was calculated as the fasting HDL cholesterol at week (48, 96, and 144) minus the baseline fasting HDL cholesterol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides Level From Baseline","description":"Only fasting results are included. Change was calculated as the fasting triglycerides at week (48, 96, and 144) minus the baseline fasting triglycerides.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"-9","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"-9","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"-4","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose Level From Baseline","description":"Only fasting results are included. Change was calculated as the fasting plasma glucose at week (48, 96, and 144) minus the baseline fasting plasma glucose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Framingham 10-year Risk of MI or Coronary Death From Baseline","description":"Only risk score estimated with fasting lipid results were included. Change was calculated as the Framingham 10-year risk of MI or coronary death at week (48, 96, and 144) minus the baseline Framingham 10-year risk of MI or coronary death. Framingham 10-year risk of MI or coronary death was calculated using Hear Coronary Heart Disease (10-year risk) found at https://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/hard-10-year-risk.php.\n\nFramingham 10-year risk of MI or coronary death was calculated according to age, laboratory values of total cholesterol and HDL cholesterol, smoking status, systolic blood pressure, and treatment for hypertension. The Framingham 10-year risk of MI or coronary death was calculated as: for males: \\<0 point (\\<1 percent risk) up to ≥17 points (≥30 percent risk); whereas for females: \\<9 points (\\<1 percent risk) up to ≥25 points (≥30 percent risk). Higher scores indicate high cardiovascular risk.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference From Baseline","description":"Change was calculated as the waist circumference (based on mid-waist circumference) at week (48, 96, and 144) minus the baseline waist circumference.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Waist:Height Ratio From Baseline","description":"Change was calculated as the waist:height ratio at week (48, 96, and 144) minus the baseline waist:height ratio.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"0.02","spread":null},{"groupId":"OG002","value":"0.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null},{"groupId":"OG001","value":"0.02","spread":null},{"groupId":"OG002","value":"0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null},{"groupId":"OG001","value":"0.02","spread":null},{"groupId":"OG002","value":"0.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Self-reported Adherence","description":"Self-reported percentage of anti-HIV medications participant had taken during the last month at weeks 4, 24, 48, 96, and 144.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":139,"n":605},"commonTop":["Blood cholesterol increased","Low density lipoprotein increased","Blood bilirubin increased","Blood glucose increased","Blood creatinine increased"]}}}